查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美的紫杉烷市場 - 產業趨勢和至2029年的預測
市場調查報告書
商品編碼
1100127

北美的紫杉烷市場 - 產業趨勢和至2029年的預測

NA Taxane Market - Industry Trends and Forecast to 2029
出版日期: | 出版商: Data Bridge Market Research | 英文 202 Pages | 商品交期: 請詢問到貨日

價格

北美的紫杉烷的市場規模，預計2022年～2029年的預測期間以7.7％的年複合成長率擴大。

本報告提供北美的紫杉烷市場相關調查，市場概要，以及各類型，各用途，各藥物類型，各製劑，各年齡層，各終端用戶，各流通管道，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 重要考察

第5章 流行病學

第6章 產業洞察

第7章 北美的紫杉烷市場:法規

第8章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第9章 北美的紫杉烷市場，各類型

  • 概要
  • Paclitaxel
  • Docetaxel
  • Cabazitaxel

第10章 北美的紫杉烷市場，各用途

  • 概要
  • 乳癌
  • 非小細胞肺癌
  • 胰臟癌
  • 卵巢癌
  • 前列腺癌
  • 其他

第11章 北美的紫杉烷市場，各藥物類型

  • 概要
  • 學名藥
  • 品牌藥

第12章 北美的紫杉烷市場，各製劑

  • 概要
  • 微脂體
  • 奈米粒子
  • 高分子奈米微胞
  • 其他

第13章 北美的紫杉烷市場，各年齡層

  • 概要
  • 成人
  • 老年人

第14章 北美的紫杉烷市場，各終端用戶

  • 概要
  • 醫院
  • 門診外科中心
  • 專門診所
  • 其他

第15章 北美的紫杉烷市場，各流通管道

  • 概要
  • 零售
    • 院內藥局
    • 零售藥局
    • 線上藥局
  • 直接競標

第16章 北美的紫杉烷市場，各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥

第17章 北美的紫杉烷市場:企業形勢

  • 企業佔有率分析:北美

第18章 SWOT分析

第19章 企業簡介

  • BRISTOL-MYERS SQUIBB COMPANY
  • SANOFI-AVENTIS U.S. LLC
  • VIATRIS INC.
  • SANDOZ INTERNATIONAL GMBH
  • FRESENIUS KABI AG
  • HIKMA PHARMACEUTICALS PLC
  • ACCORD HEALTHCARE
  • AQVIDA GMBH
  • AUREATE HEALTHCARE
  • CIPLA INC.
  • DR. REDDY'S LABORATORIES LTD.
  • ELEVAR THERAPEUTICS
  • HETERO HEALTHCARE LIMITED.
  • HUIANG PHARMACEUTICAL CO LTD
  • INGENUS PHARMACEUTICALS, LLC
  • LUYE PHARMA GROUP
  • PANACEA BIOTEC
  • PFIZER INC.
  • RPG LIFE SCIENCES LIMITED
  • SAMARTH LIFE SCIENCES PVT. LTD.
  • SAMYANG HOLDINGS CORPORATION.
  • SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
  • TORRENT PHARMACEUTICALS LTD
  • TAXANE HEALTHCARE

第20章 問卷調查

第21章 相關報告

North America taxane market is projected to register a substantial CAGR of 7.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

North America Taxane Market, By Type (Paclitaxel, Docetaxel, Cabazitaxel), Drug Type (Generics, Branded), Formulation (Liposomes, Nanoparticles, Polymeric Micelles, Others), Age Group (Adults, Geriatric), Application (Breast Cancer, Non-Small Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others) Distribution Channel (Retail Sales, Direct Tender), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029

North America taxane market is categorized into seven notable segment which is type, drug type, formulation, age group, application, end user and distribution channel.

On the basis of type, the North America taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.

On the basis of application, the North America taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and other

On the basis of drug type, the North America taxane market is segmented into branded and generics

On the basis of formulation, the North America taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others

On the basis of age group, the North America taxane market is segmented into adults and geriatric

On the basis of end user, the North America taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others

On the basis of distribution channel, the North America taxane market is segmented into direct tender, retail sales

Some of the major factors contributing to the growth of the North America taxane market are:

The rise in incidence of cancer

The funding by the government and investment in research and development

Market Players:

The key market players for North America taxane market are listed below:

Panacea Biotec

RPG Life Sciences Limited.

Aureate Healthcare

Cipla Inc.

Hetero Healthcare Limited.

AqVida GmbH

Ingenus Pharmaceuticals, LLC

TABLE OF CONTENTS

1 INTRODUCTION 38

  • 1.1 OBJECTIVES OF THE STUDY 38
  • 1.2 MARKET DEFINITION 38
  • 1.3 OVERVIEW OF NORTH AMERICA TAXANE MARKET 38
  • 1.4 CURRENCY AND PRICING 40
  • 1.5 LIMITATIONS 40
  • 1.6 MARKETS COVERED 41

2 MARKET SEGMENTATION 45

  • 2.1 MARKETS COVERED 45
  • 2.2 GEOGRAPHICAL SCOPE 46
  • 2.3 YEARS CONSIDERED FOR THE STUDY 47
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
  • 2.6 MULTIVARIATE MODELLING 52
  • 2.7 MARKET APPLICATION COVERAGE GRID 52
  • 2.8 TYPE LIFELINE CURVE 53
  • 2.9 DBMR MARKET POSITION GRID 54
  • 2.10 VENDOR SHARE ANALYSIS 56
  • 2.11 SECONDARY SOURCES 57
  • 2.12 ASSUMPTIONS 57

3 EXECUTIVE SUMMARY 58

4 PREMIUM INSIGHT 62

  • 4.1 PESTEL_ANALYSIS 63
  • 4.2 PORTER'S FIVE FORCES MODEL 64

5 EPIDEMIOLOGY 65

6 INDUSTRIAL INSIGHTS 66

  • 6.1 CONCLUSION 67

7 NORTH AMERICA TAXANE MARKET: REGULATIONS 68

 

8 MARKET OVERVIEW 73

  • 8.1 DRIVERS 75
    • 8.1.1 THE RISE IN INCIDENCE OF CANCER 75
    • 8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT 76
    • 8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS 76
    • 8.1.4 USE OF REIMBURSEMENT FOR TAXANE 77
  • 8.2 RESTRAINTS 77
    • 8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS 77
    • 8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT 78
    • 8.2.3 RISE IN PRODUCT RECALLS 78
  • 8.3 OPPORTUNITIES 79
    • 8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 79
    • 8.3.2 RISE IN HEALTHCARE EXPENDITURE 79
  • 8.4 CHALLENGES 80
    • 8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT 80
    • 8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT 80

9 NORTH AMERICA TAXANE MARKET, BY TYPE 82

  • 9.1 OVERVIEW 83
  • 9.2 PACLITAXEL 86
    • 9.2.1 BY TYPE 86
      • 9.2.1.1 SEMI-SYNTHETIC 87
      • 9.2.1.2 NATURAL 87
    • 9.2.2 BY STRENGTH 87
      • 9.2.2.1 100MG 87
      • 9.2.2.2 200MG 87
      • 9.2.2.3 250MG 87
      • 9.2.2.4 30MG 87
      • 9.2.2.5 260MG 87
      • 9.2.2.6 300MG 88
  • 9.3 DOCETAXEL 88
    • 9.3.1 120MG 89
    • 9.3.2 80MG 89
    • 9.3.3 20MG 89
    • 9.3.4 40MG 89
    • 9.3.5 60MG 89
  • 9.4 CABAZITAXEL 89
    • 9.4.1 60MG 90

 

10 NORTH AMERICA TAXANE MARKET, BY APPLICATION 91

  • 10.1 OVERVIEW 92
  • 10.2 BREAST CANCER 95
  • 10.3 NON-SMALL CELL LUNG CANCER 95
  • 10.4 PANCREATIC CANCER 96
  • 10.5 OVARIAN CANCER 97
  • 10.6 PROSTATE CANCER 97
  • 10.7 OTHERS 98

11 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE 99

  • 11.1 OVERVIEW 100
  • 11.2 GENERICS 103
  • 11.3 BRANDED 104

12 NORTH AMERICA TAXANE MARKET, BY FORMULATION 105

  • 12.1 OVERVIEW 106
  • 12.2 LIPOSOMES 109
  • 12.3 NANOPARTICLES 109
  • 12.4 POLYMERIC MICELLES 110
  • 12.5 OTHERS 111

13 NORTH AMERICA TAXANE MARKET, BY AGE GROUP 112

  • 13.1 OVERVIEW 113
  • 13.2 ADULT 116
    • 13.2.1 FEMALE 117
    • 13.2.2 MALE 117
  • 13.3 GERIATRIC 117
    • 13.3.1 FEMALE 118
    • 13.3.2 MALE 118

14 NORTH AMERICA TAXANE MARKET, BY END USER 119

  • 14.1 OVERVIEW 120
  • 14.2 HOSPITALS 123
  • 14.3 AMBULATORY SURGICAL CENTERS 123
  • 14.4 SPECIALTY CLINICS 124
  • 14.5 OTHERS 125

 

15 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL 126

  • 15.1 OVERVIEW 127
  • 15.2 RETAIL SALES 130
    • 15.2.1 HOSPITAL PHARMACY 130
    • 15.2.2 RETAIL PHARMACY 131
    • 15.2.3 ONLINE PHARMACY 131
  • 15.3 DIRECT TENDER 131

16 NORTH AMERICA TAXANE MARKET, BY REGION 132

  • 16.1 NORTH AMERICA 133
    • 16.1.1 U.S. 142
    • 16.1.2 CANADA 146
    • 16.1.3 MEXICO 150

17 NORTH AMERICA TAXANE MARKET: COMPANY LANDSCAPE 154

  • 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 154

18 SWOT ANALYSIS 155

19 COMPANY PROFILE 156

  • 19.1 BRISTOL-MYERS SQUIBB COMPANY 156
    • 19.1.1 COMPANY SNAPSHOT 156
    • 19.1.2 REVENUE ANALYSIS 156
    • 19.1.3 COMPANY SHARE ANALYSIS 157
    • 19.1.4 PRODUCT PORTFOLIO 157
    • 19.1.5 RECENT DEVELOPMENTS 157
  • 19.2 SANOFI-AVENTIS U.S. LLC 159
    • 19.2.1 COMPANY SNAPSHOT 159
    • 19.2.2 REVENUE ANALYSIS 159
    • 19.2.3 COMPANY SHARE ANALYSIS 160
    • 19.2.4 PRODUCT PORTFOLIO 160
    • 19.2.5 RECENT DEVELOPMENTS 160
  • 19.3 VIATRIS INC. 162
    • 19.3.1 COMPANY SNAPSHOT 162
    • 19.3.2 REVENUE ANALYSIS 162
    • 19.3.3 COMPANY SHARE ANALYSIS 163
    • 19.3.4 PRODUCT PORTFOLIO 163
    • 19.3.5 RECENT DEVELOPMENT 163

 

  • 19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION) 164
    • 19.4.1 COMPANY SNAPSHOT 164
    • 19.4.2 REVENUE ANALYSIS 164
    • 19.4.3 COMPANY SHARE ANALYSIS 165
    • 19.4.4 PRODUCT PORTFOLIO 165
    • 19.4.5 RECENT DEVELOPMENTS 166
  • 19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA ) 167
    • 19.5.1 COMPANY SNAPSHOT 167
    • 19.5.2 REVENUE ANALYSIS 167
    • 19.5.3 COMPANY SHARE ANALYSIS 168
    • 19.5.4 PRODUCT PORTFOLIO 168
    • 19.5.5 RECENT DEVELOPMENTS 168
  • 19.6 HIKMA PHARMACEUTICALS PLC 170
    • 19.6.1 COMPANY SNAPSHOT 170
    • 19.6.2 REVENUE ANALYSIS 170
    • 19.6.3 PRODUCT PORTFOLIO 171
    • 19.6.4 RECENT DEVELOPMENTS 171
  • 19.7 ACCORD HEALTHCARE 172
    • 19.7.1 COMPANY SNAPSHOT 172
    • 19.7.2 PRODUCT PORTFOLIO 172
    • 19.7.3 RECENT DEVELOPMENTS 172
  • 19.8 AQVIDA GMBH 173
    • 19.8.1 COMPANY SNAPSHOT 173
    • 19.8.2 PRODUCT PORTFOLIO 173
    • 19.8.3 RECENT DEVELOPMENTS 173
  • 19.9 AUREATE HEALTHCARE 174
    • 19.9.1 COMPANY SNAPSHOT 174
    • 19.9.2 PRODUCT PORTFOLIO 174
    • 19.9.3 RECENT DEVELOPMENTS 174
  • 19.10 CIPLA INC. 175
    • 19.10.1 COMPANY SNAPSHOT 175
    • 19.10.2 REVENUE ANALYSIS 175
    • 19.10.3 PRODUCT PORTFOLIO 176
    • 19.10.4 RECENT DEVELOPMENTS 176
  • 19.11 DR. REDDY'S LABORATORIES LTD. 177
    • 19.11.1 COMPANY SNAPSHOT 177
    • 19.11.2 REVENUE ANALYSIS 177
    • 19.11.3 PRODUCT PORTFOLIO 178
    • 19.11.4 RECENT DEVELOPMENTS 178

 

  • 19.12 ELEVAR THERAPEUTICS 179
    • 19.12.1 COMPANY SNAPSHOT 179
    • 19.12.2 PRODUCT PORTFOLIO 179
    • 19.12.3 RECENT DEVELOPMENTS 179
  • 19.13 HETERO HEALTHCARE LIMITED. 181
    • 19.13.1 COMPANY SNAPSHOT 181
    • 19.13.2 PRODUCT PORTFOLIO 181
    • 19.13.3 RECENT DEVELOPMENTS 181
  • 19.14 HUIANG PHARMACEUTICAL CO LTD 182
    • 19.14.1 COMPANY SNAPSHOT 182
    • 19.14.2 PRODUCT PORTFOLIO 182
    • 19.14.3 RECENT DEVELOPMENTS 182
  • 19.15 INGENUS PHARMACEUTICALS, LLC 183
    • 19.15.1 COMPANY SNAPSHOT 183
    • 19.15.2 PRODUCT PORTFOLIO 183
    • 19.15.3 RECENT DEVELOPMENTS 183
  • 19.16 LUYE PHARMA GROUP 184
    • 19.16.1 COMPANY SNAPSHOT 184
    • 19.16.2 REVENUE ANALYSIS 184
    • 19.16.3 PRODUCT PORTFOLIO 185
    • 19.16.4 RECENT DEVELOPMENTS 185
  • 19.17 PANACEA BIOTEC 186
    • 19.17.1 COMPANY SNAPSHOT 186
    • 19.17.2 REVENUE ANALYSIS 186
    • 19.17.3 PRODUCT PORTFOLIO 187
    • 19.17.4 RECENT DEVELOPMENTS 187
  • 19.18 PFIZER INC. 188
    • 19.18.1 COMPANY SNAPSHOT 188
    • 19.18.2 REVENUE ANALYSIS 188
    • 19.18.3 PRODUCT PORTFOLIO 189
    • 19.18.4 RECENT DEVELOPMENTS 189
  • 19.19 RPG LIFE SCIENCES LIMITED 190
    • 19.19.1 COMPANY SNAPSHOT 190
    • 19.19.2 REVENUE ANALYSIS 190
    • 19.19.3 PRODUCT PORTFOLIO 191
    • 19.19.4 RECENT DEVELOPMENTS 191
  • 19.20 SAMARTH LIFE SCIENCES PVT. LTD. 192
    • 19.20.1 COMPANY SNAPSHOT 192
    • 19.20.2 PRODUCT PORTFOLIO 192
    • 19.20.3 RECENT DEVELOPMENTS 192
  • 19.21 SAMYANG HOLDINGS CORPORATION. 193
    • 19.21.1 COMPANY SNAPSHOT 193
    • 19.21.2 REVENUE ANALYSIS 193
    • 19.21.3 PRODUCT PORTFOLIO 194
    • 19.21.4 RECENT DEVELOPMENTS 194
  • 19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC. 195
    • 19.22.1 COMPANY SNAPSHOT 195
    • 19.22.2 PRODUCT PORTFOLIO 195
    • 19.22.3 RECENT DEVELOPMENTS 195
  • 19.23 TORRENT PHARMACEUTICALS LTD 196
    • 19.23.1 COMPANY SNAPSHOT 196
    • 19.23.2 REVENUE ANALYSIS 196
    • 19.23.3 PRODUCT PORTFOLIO 197
    • 19.23.4 RECENT DEVELOPMENTS 197
  • 19.24 TAXANE HEALTHCARE 198
    • 19.24.1 COMPANY SNAPSHOT 198
    • 19.24.2 PRODUCT PORTFOLIO 198
    • 19.24.3 RECENT DEVELOPMENTS 198

20 QUESTIONNAIRE 199

21 RELATED REPORTS 202

LIST OF TABLES

  • TABLE 1 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 64
  • TABLE 2 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 65
  • TABLE 3 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 65
  • TABLE 4 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 66
  • TABLE 5 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 6 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 67
  • TABLE 7 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 68
  • TABLE 8 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 69
  • TABLE 9 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 73
  • TABLE 10 NORTH AMERICA BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 74
  • TABLE 11 NORTH AMERICA NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 75
  • TABLE 12 NORTH AMERICA PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 75
  • TABLE 13 NORTH AMERICA OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 76
  • TABLE 14 NORTH AMERICA PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 77
  • TABLE 15 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 77
  • TABLE 16 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 81
  • TABLE 17 NORTH AMERICA GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 82
  • TABLE 18 NORTH AMERICA BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 83
  • TABLE 19 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 87
  • TABLE 20 NORTH AMERICA LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 88
  • TABLE 21 NORTH AMERICA NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 89
  • TABLE 22 NORTH AMERICA POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 89
  • TABLE 23 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 90
  • TABLE 24 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION) 94
  • TABLE 25 NORTH AMERICA ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 95
  • TABLE 26 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 95
  • TABLE 27 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 96
  • TABLE 28 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 97
  • TABLE 29 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION) 101
  • TABLE 30 NORTH AMERICA HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 102
  • TABLE 31 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 103
  • TABLE 32 NORTH AMERICA SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 103
  • TABLE 33 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 104
  • TABLE 34 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 108
  • TABLE 35 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 109
  • TABLE 36 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 109
  • TABLE 37 NORTH AMERICA DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION) 110
  • TABLE 38 NORTH AMERICA TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 117
  • TABLE 39 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 117
  • TABLE 40 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 117
  • TABLE 41 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 117
  • TABLE 42 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 118
  • TABLE 43 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 118
  • TABLE 44 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 118
  • TABLE 45 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 118
  • TABLE 46 NORTH AMERICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 119
  • TABLE 47 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION) 119
  • TABLE 48 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 119
  • TABLE 49 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 119
  • TABLE 50 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION) 119
  • TABLE 51 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 120
  • TABLE 52 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 120
  • TABLE 53 U.S. TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 121
  • TABLE 54 U.S. PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 121
  • TABLE 55 U.S. TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 121
  • TABLE 56 U.S. TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 121
  • TABLE 57 U.S. TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 122
  • TABLE 58 U.S. PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 122
  • TABLE 59 U.S. DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 122
  • TABLE 60 U.S. CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 122
  • TABLE 61 U.S. TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION) 123
  • TABLE 62 U.S. ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 123
  • TABLE 63 U.S. GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 123
  • TABLE 64 U.S. TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION) 123
  • TABLE 65 U.S. TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 123
  • TABLE 66 U.S. RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 124
  • TABLE 67 CANADA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 68 CANADA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 69 CANADA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 125
  • TABLE 70 CANADA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 71 CANADA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 126
  • TABLE 72 CANADA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 126
  • TABLE 73 CANADA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 126
  • TABLE 74 CANADA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 126
  • TABLE 75 CANADA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION) 127
  • TABLE 76 CANADA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 127
  • TABLE 77 CANADA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 127
  • TABLE 78 CANADA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION) 127
  • TABLE 79 CANADA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 127
  • TABLE 80 CANADA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 128
  • TABLE 81 MEXICO TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 82 MEXICO PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 83 MEXICO TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 129
  • TABLE 84 MEXICO TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 85 MEXICO TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 130
  • TABLE 86 MEXICO PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 130
  • TABLE 87 MEXICO DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 130
  • TABLE 88 MEXICO CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION) 130
  • TABLE 89 MEXICO TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION) 131
  • TABLE 90 MEXICO ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 131
  • TABLE 91 MEXICO GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION) 131
  • TABLE 92 MEXICO TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION) 131
  • TABLE 93 MEXICO TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 131
  • TABLE 94 MEXICO RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 132

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA TAXANE MARKET: SEGMENTATION 23
  • FIGURE 2 NORTH AMERICA TAXANE MARKET: DATA TRIANGULATION 26
  • FIGURE 3 NORTH AMERICA TAXANE MARKET: DROC ANALYSIS 27
  • FIGURE 4 NORTH AMERICA TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 28
  • FIGURE 5 NORTH AMERICA TAXANE MARKET: COMPANY RESEARCH ANALYSIS 28
  • FIGURE 6 NORTH AMERICA TAXANE MARKET: INTERVIEW DEMOGRAPHICS 29
  • FIGURE 7 NORTH AMERICA TAXANE MARKET: MARKET APPLICATION COVERAGE GRID 30
  • FIGURE 8 NORTH AMERICA TAXANE MARKET: DBMR MARKET POSITION GRID 32
  • FIGURE 9 NORTH AMERICA TAXANE MARKET: VENDOR SHARE ANALYSIS 34
  • FIGURE 10 NORTH AMERICA TAXANE MARKET: SEGMENTATION 38
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 39
  • FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE NORTH AMERICA TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 40
  • FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TAXANE MARKET IN 2022 & 2029 40
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TAXANE MARKET 52
  • FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020 53
  • FIGURE 16 NORTH AMERICA TAXANE MARKET: BY TYPE, 2021 61
  • FIGURE 17 NORTH AMERICA TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION) 62
  • FIGURE 18 NORTH AMERICA TAXANE MARKET: BY TYPE, CAGR (2022-2029) 62
  • FIGURE 19 NORTH AMERICA TAXANE MARKET: BY TYPE, LIFELINE CURVE 63
  • FIGURE 20 NORTH AMERICA TAXANE MARKET: BY APPLICATION, 2021 70
  • FIGURE 21 NORTH AMERICA TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 71
  • FIGURE 22 NORTH AMERICA TAXANE MARKET: BY APPLICATION, CAGR (2022-2029) 71
  • FIGURE 23 NORTH AMERICA TAXANE MARKET: BY APPLICATION, LIFELINE CURVE 72
  • FIGURE 24 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, 2021 78
  • FIGURE 25 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 79
  • FIGURE 26 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029) 79
  • FIGURE 27 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE 80
  • FIGURE 28 NORTH AMERICA TAXANE MARKET: BY FORMULATION, 2021 84
  • FIGURE 29 NORTH AMERICA TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION) 85
  • FIGURE 30 NORTH AMERICA TAXANE MARKET: BY FORMULATION, CAGR (2022-2029) 85
  • FIGURE 31 NORTH AMERICA TAXANE MARKET: BY FORMULATION, LIFELINE CURVE 86
  • FIGURE 32 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, 2021 91
  • FIGURE 33 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION) 92
  • FIGURE 34 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029) 92
  • FIGURE 35 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE 93
  • FIGURE 36 NORTH AMERICA TAXANE MARKET: BY END USER, 2021 98
  • FIGURE 37 NORTH AMERICA TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION) 99
  • FIGURE 38 NORTH AMERICA TAXANE MARKET: BY END USER, CAGR (2022-2029) 99
  • FIGURE 39 NORTH AMERICA TAXANE MARKET: BY END USER, LIFELINE CURVE 100
  • FIGURE 40 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021 105
  • FIGURE 41 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 106
  • FIGURE 42 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 106
  • FIGURE 43 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 107
  • FIGURE 44 NORTH AMERICA TAXANE MARKET: SNAPSHOT (2021) 112
  • FIGURE 45 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2021) 114
  • FIGURE 46 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2022 & 2029) 114
  • FIGURE 47 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2021 & 2029) 115
  • FIGURE 48 NORTH AMERICA TAXANE MARKET: BY TYPE (2022-2029) 115
  • FIGURE 49 NORTH AMERICA TAXANE MARKET: COMPANY SHARE 2021 (%) 132